You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBromfenac
Accession NumberDB00963  (APRD00831)
TypeSmall Molecule
GroupsApproved
DescriptionBromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool to optimize surgical outcomes.
Structure
Thumb
Synonyms
[2-Amino-3-(4-bromo-benzoyl)-phenyl]-acetic acid
2-amino-3-(4-Bromobenzoyl)benzeneacetic acid
Bromfenaco
Bromfenacum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BromdaySolution / drops.9 mg/mLOphthalmicUnit Dose Services2010-09-20Not applicableUs
BromdaySolution / drops.9 mg/mLOphthalmicPhysicians Total Care, Inc.2011-09-30Not applicableUs
BromdaySolution / drops.9 mg/mLOphthalmicIsta Pharmaceuticals, Inc2010-09-20Not applicableUs
Bromsite 0.075%Solution / drops.76 mg/mLOphthalmicSun Pharmaceutical Industries, Inc.2016-05-01Not applicableUs
ProlensaSolution / drops.7 mg/mLOphthalmicBausch & Lomb Incorporated2013-04-05Not applicableUs
ProlensaSolution0.07 %OphthalmicBausch & Lomb Inc2015-09-25Not applicableCanada
YelloxSolution / drops0.9 mg/mlOphthalmicCroma Pharma Gmb H2011-05-18Not applicableEu
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BromfenacSolution / drops.9 mg/mLOphthalmicMylan Pharmaceuticals, Inc.2011-05-11Not applicableUs
BromfenacSolution / drops1.035 mg/mLOphthalmicPhysicians Total Care, Inc.2012-04-13Not applicableUs
BromfenacSolution / drops.9 mg/mLOphthalmicMylan Pharmaceuticals, Inc.2011-05-11Not applicableUs
BromfenacSolution / drops.9 mg/mLOphthalmicMylan Pharmaceuticals, Inc.2011-05-11Not applicableUs
BromfenacSolution / drops.9 mg/mLOphthalmicApotex Corp2014-06-19Not applicableUs
BromfenacSolution / drops1.035 mg/mLOphthalmicHi Tech Pharmacal Co., Inc.2014-01-22Not applicableUs
Bromfenac Ophthalmic Solution, 0.09%Solution / drops1.035 mg/mLOphthalmicApotex Corp.2014-06-23Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DuractWyeth-Ayerst
XibromISTA Pharmaceuticals
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Bromfenac sodium
120638-55-3
Thumb
  • InChI Key: PPOSVVJOVKVBPW-UHFFFAOYSA-L
  • Monoisotopic Mass: 763.995695148
  • Average Mass: 766.339
DBSALT000356
Categories
UNII864P0921DW
CAS number91714-94-2
WeightAverage: 334.165
Monoisotopic: 333.000055902
Chemical FormulaC15H12BrNO3
InChI KeyZBPLOVFIXSTCRZ-UHFFFAOYSA-N
InChI
InChI=1S/C15H12BrNO3/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19/h1-7H,8,17H2,(H,18,19)
IUPAC Name
2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid
SMILES
NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1
Pharmacology
IndicationFor the treatment of postoperative inflammation in patients who have undergone cataract extraction.
Structured Indications
PharmacodynamicsBromfenac ophthalmic solution is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use.
Mechanism of actionThe mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Prostaglandin G/H synthase 1Proteinunknown
inhibitor
HumanP23219 details
Related Articles
AbsorptionThe plasma concentration of bromfenac following ocular administration in humans is unknown.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Bromfenac Action PathwayDrug actionSMP00102
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Bromfenac is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Bromfenac is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Bromfenac is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Bromfenac is combined with 5-androstenedione.Experimental, Illicit
AbciximabBromfenac may increase the anticoagulant activities of Abciximab.Approved
AcebutololBromfenac may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Aceclofenac.Approved
AcenocoumarolBromfenac may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Bromfenac.Approved, Vet Approved
AclarubicinBromfenac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Bromfenac.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Alendronic acid.Approved
AliskirenBromfenac may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololBromfenac may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Bromfenac.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Amcinonide.Approved
AmikacinBromfenac may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideBromfenac may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinBromfenac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodBromfenac may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Bromfenac is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Bromfenac is combined with Anisodamine.Investigational
annamycinBromfenac may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Bromfenac is combined with Antipyrine.Approved
Antithrombin III humanBromfenac may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Bromfenac may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanBromfenac may increase the anticoagulant activities of Apixaban.Approved
ApramycinBromfenac may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Bromfenac is combined with Apremilast.Approved, Investigational
ArbekacinBromfenac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinBromfenac may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanBromfenac may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololBromfenac may decrease the antihypertensive activities of Arotinolol.Approved
AtenololBromfenac may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Bromfenac is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Bromfenac.Approved
BalsalazideBromfenac may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminBromfenac may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololBromfenac may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Bromfenac.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Bromfenac.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Bromfenac.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Betamethasone.Approved, Vet Approved
BetaxololBromfenac may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Betulinic Acid.Investigational
BevantololBromfenac may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Bromfenac.Approved, Investigational
BisoprololBromfenac may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinBromfenac may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololBromfenac may decrease the antihypertensive activities of Bopindolol.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bromfenac is combined with Bucillamine.Investigational
BucindololBromfenac may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Budesonide.Approved
BufuralolBromfenac may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideBromfenac may decrease the diuretic activities of Bumetanide.Approved
BupranololBromfenac may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Bromfenac.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Bromfenac.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Bromfenac.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Bromfenac.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Bromfenac.Approved, Vet Approved, Withdrawn
CarteololBromfenac may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolBromfenac may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Bromfenac is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Bromfenac is combined with Celecoxib.Approved, Investigational
CeliprololBromfenac may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinBromfenac may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Bromfenac.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bromfenac.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Bromfenac.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Bromfenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Bromfenac.Approved
CinoxacinBromfenac may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinBromfenac may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidBromfenac may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Bromfenac is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Bromfenac.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Bromfenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Bromfenac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Bromfenac is combined with Curcumin.Investigational
CyclosporineBromfenac may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Bromfenac is combined with D-Limonene.Investigational
Dabigatran etexilateBromfenac may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinBromfenac may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidBromfenac may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinBromfenac may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Bromfenac is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Bromfenac is combined with dehydroepiandrosterone sulfate.Investigational
DesirudinBromfenac may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Bromfenac.Approved
DextranBromfenac may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Bromfenac may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Bromfenac may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Bromfenac may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Bromfenac.Approved, Vet Approved
DicoumarolBromfenac may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Bromfenac.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Bromfenac.Approved
DihydrostreptomycinBromfenac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Bromfenac.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Bromfenac.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Bromfenac.Approved
DoxorubicinBromfenac may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneBromfenac may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Bromfenac is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Bromfenac is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Bromfenac is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ebselen.Investigational
Edetic AcidBromfenac may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanBromfenac may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Bromfenac.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Bromfenac.Approved
EnoxacinBromfenac may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinBromfenac may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Bromfenac is combined with Epirizole.Approved
EpirubicinBromfenac may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneBromfenac may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Bromfenac.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Bromfenac.Approved
EquileninThe risk or severity of adverse effects can be increased when Bromfenac is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Equilin.Approved
EsmololBromfenac may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Estrone sulfate.Approved
Etacrynic acidBromfenac may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Bromfenac.Approved, Investigational
Ethyl biscoumacetateBromfenac may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Bromfenac is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Bromfenac is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Bromfenac is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Bromfenac.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Bromfenac.Vet Approved
FleroxacinBromfenac may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Bromfenac.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Bromfenac is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fludrocortisone.Approved
FluindioneBromfenac may increase the anticoagulant activities of Fluindione.Investigational
FlumequineBromfenac may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Bromfenac.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Bromfenac.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Bromfenac.Approved, Nutraceutical, Vet Approved
FondaparinuxBromfenac may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumBromfenac may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Bromfenac.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bromfenac.Approved
FramycetinBromfenac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideBromfenac may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateBromfenac may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinBromfenac may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinBromfenac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Bromfenac.Approved, Withdrawn
GemifloxacinBromfenac may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinBromfenac may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinBromfenac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ABromfenac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinBromfenac may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Bromfenac is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Bromfenac is combined with HE3286.Investigational
HeparinBromfenac may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Bromfenac is combined with Higenamine.Investigational
HirulogBromfenac may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Bromfenac is combined with HMPL-004.Investigational
HydralazineBromfenac may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Bromfenac.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Bromfenac.Approved
Hygromycin BBromfenac may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Bromfenac is combined with Icatibant.Approved
IdarubicinBromfenac may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxBromfenac may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Bromfenac.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Bromfenac.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Bromfenac.Approved
IndenololBromfenac may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Bromfenac.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Indoprofen.Withdrawn
INNO-206Bromfenac may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bromfenac.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Bromfenac is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Bromfenac is combined with Istaroxime.Investigational
KanamycinBromfenac may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Bromfenac.Approved
LabetalolBromfenac may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Bromfenac.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Leflunomide.Approved, Investigational
LepirudinBromfenac may increase the anticoagulant activities of Lepirudin.Approved
LevobunololBromfenac may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinBromfenac may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Bromfenac.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Bromfenac.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Bromfenac is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Bromfenac.Approved
LomefloxacinBromfenac may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Bromfenac is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Bromfenac.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Bromfenac.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Bromfenac is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Bromfenac.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Bromfenac.Approved
ME-609The risk or severity of adverse effects can be increased when Bromfenac is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Bromfenac.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Bromfenac.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Bromfenac is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Bromfenac.Approved, Vet Approved
MesalazineBromfenac may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Bromfenac is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Bromfenac.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Bromfenac.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Methylprednisolone.Approved, Vet Approved
MetipranololBromfenac may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Bromfenac.Approved
MetoprololBromfenac may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideBromfenac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Bromfenac.Approved
MizoribineThe risk or severity of adverse effects can be increased when Bromfenac is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Bromfenac.Approved
MometasoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Bromfenac.Approved
MoxifloxacinBromfenac may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Bromfenac.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Nabumetone.Approved
NadololBromfenac may decrease the antihypertensive activities of Nadolol.Approved
NadroparinBromfenac may increase the anticoagulant activities of Nadroparin.Approved
NafamostatBromfenac may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Bromfenac.Approved
Nalidixic AcidBromfenac may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Bromfenac.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Bromfenac is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Bromfenac is combined with NCX 4016.Investigational
NeamineBromfenac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinBromfenac may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinBromfenac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Nepafenac.Approved
NetilmicinBromfenac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Nitroaspirin.Investigational
NorfloxacinBromfenac may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinBromfenac may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Bromfenac.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bromfenac.Approved
OlsalazineBromfenac may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Bromfenac.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Orgotein.Vet Approved
OtamixabanBromfenac may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Oxaprozin.Approved
OxprenololBromfenac may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Bromfenac is combined with Parecoxib.Approved
ParomomycinBromfenac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinBromfenac may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinBromfenac may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololBromfenac may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateBromfenac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Bromfenac.Approved
PhenindioneBromfenac may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonBromfenac may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Bromfenac.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bromfenac.Approved, Investigational
PindololBromfenac may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinBromfenac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideBromfenac may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Bromfenac.Approved, Investigational
PlicamycinBromfenac may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Bromfenac.Approved
PractololBromfenac may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Bromfenac.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Bromfenac can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Bromfenac is combined with Propacetamol.Approved
PropranololBromfenac may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Bromfenac.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Bromfenac.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Bromfenac.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Bromfenac.Vet Approved
Protein CBromfenac may increase the anticoagulant activities of Protein C.Approved
Protein S humanBromfenac may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeBromfenac may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinBromfenac may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Bromfenac is combined with PTC299.Investigational
PuromycinBromfenac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Bromfenac.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Bromfenac.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Bromfenac.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Bromfenac.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Bromfenac is combined with Resveratrol.Experimental, Investigational
ReviparinBromfenac may increase the anticoagulant activities of Reviparin.Approved
RibostamycinBromfenac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Risedronate.Approved, Investigational
RivaroxabanBromfenac may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Bromfenac is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinBromfenac may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Bromfenac.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Bromfenac.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Bromfenac.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Bromfenac.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Bromfenac is combined with Seratrodast.Approved, Investigational
SisomicinBromfenac may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolBromfenac may decrease the antihypertensive activities of Sotalol.Approved
SP1049CBromfenac may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinBromfenac may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinBromfenac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Bromfenac.Approved
SpironolactoneBromfenac may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Bromfenac is combined with SRT501.Investigational
StreptomycinBromfenac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinBromfenac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineBromfenac may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Bromfenac.Approved
SulodexideBromfenac may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Bromfenac.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Bromfenac.Approved, Withdrawn
TacrolimusBromfenac may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Bromfenac.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Bromfenac.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Bromfenac.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Bromfenac.Approved, Investigational
TemafloxacinBromfenac may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Bromfenac.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Bromfenac.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Bromfenac is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tiaprofenic acid.Approved
TiludronateThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tiludronate.Approved, Vet Approved
TimololBromfenac may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tixocortol.Approved
TobramycinBromfenac may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Bromfenac.Approved
TorasemideBromfenac may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Bromfenac.Approved
TranilastThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Bromfenac.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Bromfenac.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Bromfenac is combined with Triamcinolone.Approved, Vet Approved
TriamtereneBromfenac may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Bromfenac.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Bromfenac is combined with Trisalicylate-choline.Approved
TrovafloxacinBromfenac may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Bromfenac.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Bromfenac is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinBromfenac may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Bromfenac.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Bromfenac.Approved
WarfarinBromfenac may increase the anticoagulant activities of Warfarin.Approved
XimelagatranBromfenac may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Bromfenac may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Bromfenac is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Bromfenac.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Bromfenac is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Bromfenac is combined with Zomepirac.Withdrawn
ZorubicinBromfenac may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Shirou Sawa, “Aqueous solution preparation containing aminoglycoside antibiotic and bromfenac.” U.S. Patent US20070082857, issued April 12, 2007.

US20070082857
General ReferencesNot Available
External Links
ATC CodesS01BC11
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (41.5 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9133
Blood Brain Barrier+0.8403
Caco-2 permeable+0.5999
P-glycoprotein substrateNon-substrate0.7803
P-glycoprotein inhibitor INon-inhibitor0.663
P-glycoprotein inhibitor IINon-inhibitor0.8983
Renal organic cation transporterNon-inhibitor0.921
CYP450 2C9 substrateNon-substrate0.8624
CYP450 2D6 substrateNon-substrate0.898
CYP450 3A4 substrateNon-substrate0.7483
CYP450 1A2 substrateNon-inhibitor0.7326
CYP450 2C9 inhibitorNon-inhibitor0.6515
CYP450 2D6 inhibitorNon-inhibitor0.9003
CYP450 2C19 inhibitorNon-inhibitor0.8688
CYP450 3A4 inhibitorNon-inhibitor0.8927
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7996
Ames testNon AMES toxic0.88
CarcinogenicityNon-carcinogens0.7301
BiodegradationNot ready biodegradable0.9618
Rat acute toxicity2.5564 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9747
hERG inhibition (predictor II)Non-inhibitor0.8313
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ista pharmaceuticals
Packagers
Dosage forms
FormRouteStrength
Solution / dropsOphthalmic.9 mg/mL
Solution / dropsOphthalmic1.035 mg/mL
Solution / dropsOphthalmic.76 mg/mL
SolutionOphthalmic0.07 %
Solution / dropsOphthalmic.7 mg/mL
Solution / dropsOphthalmic0.9 mg/ml
Prices
Unit descriptionCostUnit
Xibrom 0.09% Solution 5ml Bottle289.59USD bottle
Xibrom 0.09% Solution 2.5ml Bottle148.56USD bottle
Xibrom 0.09% eye drops68.57USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8129431 No2005-09-112025-09-11Us
US8669290 No2004-01-162024-01-16Us
US8754131 No2004-01-162024-01-16Us
US8778999 No2009-09-032029-09-03Us
US8871813 No2004-01-162024-01-16Us
US8927606 No2004-01-162024-01-16Us
US9144609 No2004-01-162024-01-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0126 mg/mLALOGPS
logP3ALOGPS
logP3.66ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)3.81ChemAxon
pKa (Strongest Basic)1.59ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area80.39 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity80.26 m3·mol-1ChemAxon
Polarizability29.93 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzophenones. These are organic compounds containing a ketone attached to two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzophenones
Direct ParentBenzophenones
Alternative Parents
Substituents
  • Benzophenone
  • Diphenylmethane
  • Phenylacetate
  • Acetophenone
  • Substituted aniline
  • Aryl ketone
  • Benzoyl
  • Halobenzene
  • Bromobenzene
  • Aniline
  • Primary aromatic amine
  • Aryl halide
  • Aryl bromide
  • Vinylogous amide
  • Ketone
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Organobromide
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Waterbury LD, Silliman D, Jolas T: Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40. [PubMed:16846546 ]
  2. Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S: Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. Clin Ther. 2006 Aug;28(8):1123-32. [PubMed:16982289 ]
  3. Chitturi S, George J: Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis. 2002;22(2):169-83. [PubMed:12016548 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Waterbury LD, Silliman D, Jolas T: Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40. [PubMed:16846546 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Cho H, Wolf KJ, Wolf EJ: Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin Ophthalmol. 2009;3:199-210. Epub 2009 Jun 2. [PubMed:19668566 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 04, 2016 03:43